



15.25 credit points

Supported by



American Society of Clinical Oncology

2nd Annual

# Clinical Trials in Oncology

Tuesday 1 and Wednesday 2 December 2009, Hilton Munich City, Munich, Germany

Targeted approaches to optimising clinical research while enhancing patient enrolment, data quality and the value of your trial outcome

## JOIN OUR 19 CASE STUDY PRESENTATIONS AND:

- Understand the amended RECIST 1.1 guidelines
- Explore IPH 2101, a novel anti-Natural Killer Immunoglobulin like Receptor (KIR) monoclonal antibody that enhances NK cells cytotoxicity
- Find out how your peers increase the amount of high quality data they obtain
- Benefit from presentations and discussion sessions with your peers from pharma and biotech manufacturers as well as regulators

## COMPANIES REPRESENTED INCLUDE:

- |                           |                        |
|---------------------------|------------------------|
| • F. HOFFMANN<br>LA-ROCHE | • JOHNSON &<br>JOHNSON |
| • ZIOPHARM<br>ONCOLOGY    | • LILLY                |
| • ASTRAZENECA             | • CELGENE              |
| • GPC BIOTECH             | • PROSTRAKAN           |

## KEYNOTE SPEAKERS:

**Robert A. Morgan,**  
Senior Vice President,  
Regulatory Affairs, Quality,  
and Clinical Development,  
**ZIOPHARM ONCOLOGY**

**Thomas Pepper,**  
Clinical Research and  
Exploratory Development  
(CRED), Operations Leader  
- Oncology (COL), Clinical  
Programme Management  
- Study Management  
Group (PDEC-S), **ROCHE  
PRODUCTS**

**Michael Krams,**  
Vice President, Adaptive  
Trials and Applied  
Programme Strategies,  
ClinDev, **WYETH**

**Thomas Bogenrieder,**  
Clinical Director Oncology,  
Oncology Centre of  
Excellence, Europe,  
Asia-Pacific, Japan &  
Emerging Markets,  
**GLAXOSMITHKLINE**

**Christiane Langer,**  
Group Director  
Early Oncology, **BRISTOL-  
MYERS SQUIBB EUROPE**

**Jonathan Allis,**  
Head Global  
Imaging Network,  
**GE HEALTHCARE**

**Murray Yule,** Vice President  
Clinical Development,  
**ASTEX THERAPEUTICS**

**Clemens Stoffregen,**  
Internist, Regional Tumour  
Team Leader, European  
Platform, Oncology,  
Medical Advisor, **LILLY**

Attend the  
exciting pre-  
conference workshop  
on Monday 30  
November  
2009

Lead sponsor:



Nexus Oncology

Silver sponsors: **PPD**



Harrison  
Clinical  
Research

Harrison

Sponsor: **Cytel**

STATISTICAL SOFTWARE & SERVICES

Co-sponsor:



SIRO Clinpharm Pvt. Ltd.

## REGISTER NOW:

[www.clinicaltrialevents.com/oncology](http://www.clinicaltrialevents.com/oncology)

Email: [book@arena-international.com](mailto:book@arena-international.com)

Tel: +44 (0)207 7753 4268

Fax: +44 (0)20 7915 9773

08:30 *Registration and coffee*

09:00 **Opening remarks from the Chair**  
**Clare Wareing, CEO, NEXUS ONCOLOGY**

## Optimising patient recruitment, data capture and trial design to ensure faster regulatory approval

09:10 **Keynote address: From design to decision-making from a clinical development perspective: effective project management techniques for ensuring your study runs smoothly**

- Ensuring overall project management of trials in order to contribute to R&D excellence
  - Managing the team: what makes a good compound leader and how to coordinate the internal teams and external stakeholders
  - Establishing effective approaches to solve strategic problems and address challenges effectively
  - Implementing trial design into practice: making the right decisions to boost strategic effectiveness of your trials within drug development
- Panteli Theocharous, Senior Clinical Project Scientist (Associate Director), J & J Global Clinical Development, JOHNSON & JOHNSON**

09:40 **De-risking oncology clinical development: mitigating risk from phase I to III**

- Phase I trial design: single agent or combination studies? Solid or haematological tumours? All tumour types or disease specific patient populations?
- Cost effective phase I studies: maximising the information collected to inform decisions about phase II design and working with the right phase I sites
- Phase II study designs: the pros and cons of randomised phase II studies: indications and dilemmas
- Enriching patient populations in phase II development using biomarkers and genetics
- Feasibility assessments: how to ensure that recruitment rates quoted during feasibility are accurate
- Mitigating the risk to patient recruitment in phase II studies
- The decision to move into phase III
- Going for gold: moving straight to phase III from an expanded phase I programme

**Clare Wareing, CEO, NEXUS ONCOLOGY**

10:10 **Panel discussion: Improving the communication and cooperation between trial sponsors, academic research networks and study sites to maximise patient enrolment**

- Complying with the study sites' requirements from a sponsor's perspective to ensure a smooth enrolment process
- Identifying key obstacles with sites and sponsors to cooperate with each other in terms of patient recruitment and how to overcome them
- Specifying actions to be taken by sponsors to help the site recruit
- Assessing how networks can work more closely with sponsors and physicians on-site to enrol patients effectively
- Handling competition between oncology trials at one site: how to build a strong sponsor-site-relationship to tackle this issue successfully
- Identifying crucial action points to prevent delays with patient enrolment in order to guarantee the study starts on time

**Chair: Clare Wareing, CEO, NEXUS ONCOLOGY**

**Panellist: Prof. Christian Ohmann, Member of the Board, Network of Coordinating Centres for Clinical Trials, KKS NETWORK**

10:40 *Morning refreshments*

11:00 **Assessing the feasibility of oncology clinical trials to ensure trials stay on track at any development stage**

- Establishing the need for a feasibility assessment and the crucial points to consider to ensure an accurate measure
  - Evaluating the benefits of feasibility surveys and how to measure them
  - Outlining the sources of data that can be used to help plan oncology studies whilst ensuring the data quality is maintained
  - Providing access to the data needed: presenting a PPD case study
- Martin Lee, Executive Director, Feasibility Services, Board Certified, Internal Medicine and Medical Oncology, PPD**

11:30 **Establishing endpoints for your cancer clinical trial to get the most valuable trial outcome**

- Clarifying scientific and regulatory relevance of different endpoints
- Overall survival, natural history, cross-over and other confounding factors
- Choosing endpoints effectively according to cancer type, mechanism of action of drugs and regulatory objectives
- Assessing traditional endpoints and new candidates
- Using biomarkers as surrogate endpoints
- Relevance of overall survival if trial patients have cross-over during study or attend other post study: identifying how this endpoint can be interpreted

**Cesar Pico, Clinical Research Associate Director, CELGENE**

12:00 **Establishing innovative trial marketing approaches involving academic research networks and study sites to maximise patient enrolment**

- Realistically forecasting the number of patients to be recruited to enable efficient trial execution
- Assessing the means to proactively communicate with sites in order to accelerate the process of finding appropriate patients
- Defining the role and responsibilities of CRAs in the recruitment process: how they manage to motivate and effectively communicate with sites in order to get them actively involved
- Working with CROs to optimise the recruitment process
- Facilitating cooperation between academic research organisations and the industry to inform the maximum number of experts and patients
- Outlining options to inform patients directly about a trial to encourage them to contact a clinician
- Ensuring compliance with ethics committee guidelines
- Leveraging eHealth affinity of cancer patients
- Finding new ways of cancer clinical trial marketing

**Jody Spooner, Business Development Associate, CMED**

## Moving towards personalised cancer therapies to increase the potential value of a medicine with respect to reimbursement

12:30 **Case study: Overcoming the operational challenges of implementing a personalised healthcare strategy in early phase oncology studies**

- Developing medicines with improved and more predictable outcomes, thereby allowing the clinician to optimise the therapy
- Selecting biomarkers of interest in the context of novel molecules and identifying appropriate analytical laboratories and assay validation
- Burden on both the patient and investigational sites in the collection, processing and management of multiple samples which can be particularly challenging in the context of serial tumour biopsies
- Integrating laboratory based biomarker assessments with radiological assessments such as CT/PET or DCE-MRI within the same protocol
- Ensuring a high level of compliance consistency in sample collection both within and across clinical centres
- Obtaining the necessary ethical and regulatory approvals
- Receiving patient informed consent

**Thomas Pepper, Clinical Research and Exploratory Development (CRED), Operations Leader - Oncology (COL), Clinical Programme Management - Study Management Group (PDEC-S), ROCHE PRODUCTS**

13:00 *Lunch*

**REGISTER ONLINE NOW!**

[www.clinicaltrialevents.com/  
oncology](http://www.clinicaltrialevents.com/oncology)

## 14:00 Roundtable afternoon sessions

Delegates will be able to attend three one-hour roundtable discussion groups from a selection of key topics. Each session will be chaired by an industry expert who will facilitate an exchange of opinions, essential experiences and learning related to a current aspect of clinical trials in oncology.

### Roundtable 1

#### Exploring what strategies could be put in place to increase patient enrolment

Optimising your approaches to engage study sites, CRAs and other stakeholders like academic research networks in helping you recruit the maximum amount of patients with the right indications for your trial

**Thore Nederman, Head of Clinical Development, ACTIVE BIOTECH**

### Roundtable 2

#### Overcoming the operational challenges of implementing a personalised healthcare strategy in early phase oncology studies

Understanding techniques to move towards tailored cancer therapies in order to ensure the best outcome for each patient  
**Thomas Pepper, Clinical Research and Exploratory Development (CRED), Operations Leader - Oncology (COL), Clinical Programme Management - Study Management Group (PDEC-S), ROCHE PRODUCTS**

### Roundtable 3

#### Ensuring effective collaboration and partnership between clinical R&D and clinical operations to ensure a successful trial

Managing communication and cooperation challenges by adopting successful clinical project management strategies  
**Panteli Theocharous, Senior Clinical Project Scientist (Associate Director), J&J Global Clinical Development, JOHNSON & JOHNSON**

### Roundtable 4

#### Integrating radiotherapy into clinical trials in combination with molecular targeted agents

Overcoming complexity issues surrounding the combination of targeted therapy and radiotherapy

**Ozlem Ataman, Radiotherapy Combinations (ROCKIT) Clinical Lead, ASTRAZENECA**

### Roundtable 5

#### How to do cost effective oncology drug development

Evaluating how to increase efficiency and cost containment throughout your drug development processes without jeopardizing your trial outcome

**Clare Wareing, CEO, NEXUS ONCOLOGY**

### Roundtable 6

#### Exchanging experiences in handling biological samples to deliver reliable lab results

Understanding pre-analytical factors, handling and logistics aspects to ensure that samples arrive in good condition at the laboratory. Inter-active discussion to share experiences on biomarkers, personalized medicine and laboratory results.

**Dr. Hermann Schulz, CEO, INTERLAB central lab services**

**Dieter Sedlmair, Director Business Development, INTERLAB CENTRAL LAB SERVICES**

17:30 *Closing remarks from the Chair, and cocktail reception hosted by Nexus Oncology*



08:30 *Registration and coffee*

09:00 **Opening remarks from the Chair**

## Identifying diagnostic testing methods to evaluate the results of your oncology trial effectively through the use of the right endpoints

09:10 **Keynote address: Exploring the amended guidelines of RECIST 1.1 (Response Evaluation Criteria in Solid Tumours) and learning how to adapt them accurately**

- Understanding its use and benefits in clinical trials with a primary endpoint of objective response
  - Evaluating the tumour response: assessing tumour shrinkage and disease progression based on the sum of diameters without anatomical-based imaging
  - Outlining the relevant changes: Number of lesions to be assessed, measurement of pathological lymph nodes, confirmation of response, disease progression and imaging guidance
  - Exploring remaining issues to be defined
  - Identifying how to adapt RECIST 1.1 and leverage benefits
- Robert A. Morgan, Senior Vice President, Regulatory Affairs, Quality, and Clinical Development, ZIOPHARM ONCOLOGY**

09:40 **Case study: Moving beyond simple procedures like computed tomography (CT) to positron emission tomography (PET): highlighting advances of tumour development analysis**

- Molecular imaging: making it real
  - Imaging the hallmark of cancer with PET
  - Angiogenesis, apoptosis, proliferation
  - Enhanced amino acid transport
  - Quality control in imaging clinical trials
  - The importance of sophisticated analysis tools
- Jonathan Allis, Head Global Imaging Network, GE HEALTHCARE**

10:10 **Uncovering independent central review (ICR) for oncology clinical trials: challenges and lesson learned**

- Assessing endpoints in oncology trials and ensuring verification for regulatory approval
  - Identifying the process of an ICR as well as resources involved
  - Why ICR: outlining potential purposes and how to produce greater consistency in image interpretation
  - Clarifying operational considerations
  - Explaining discordance between local and central interpretations and how to handle this
  - Overcoming challenges regarding protocol requirements
- Karoline Meurer, Managing Director, RADPHARM**

10:40 **Establishing endpoints for your cancer clinical trial to get the most valuable trial outcome**

Explaining Primary Systemic Therapy (PST) or Neoadjuvant (Chemo) Therapy (NA(C)T) in invasive breast cancer: state-of-the-art, current issues, and future perspectives for drug development

- Broadening the indication for PST or NA(C)T from downsizing locally advanced, inoperable breast cancers to smaller breast cancers in order to allow breast conserving therapy (BCT) and to yield better cosmetic results
- Outlining the results of the large, randomized, pivotal phase III neoadjuvant trials NSABP B-18 and NSABP B-27 and explaining the advantages and disadvantages of neoadjuvant chemotherapy
- Using NA(C)T for in-vivo chemosensitivity testing and as innovative platform for the in-vivo testing of new drugs, e.g. cytotoxic and molecularly targeted agents and their combinations
- Accomplishing a pathologic complete response (pCR), i.e. the absence of invasive tumour in the breast specimen and/or in the axillary lymph nodes, which shows PST to be a surrogate end point for recurrence and survival
- Testing in-vivo chemosensitivity of new drugs and drug combinations in the neoadjuvant setting using the pCR-rate as a surrogate end point (i.e. substituting recurrence-free (RFS) and overall survival (OS) in the adjuvant setting) in order to speed up drug development in early breast cancer
- Presenting large, ongoing, neoadjuvant clinical trials applying this new

paradigm in drug development in primary breast cancers according to their molecularly defined subtypes

**Wolfgang Hamm, MD, PhD, Senior Clinical Research Physician, Harrison Clinical Research**

11:10 *Morning refreshments*

## Learning from case studies on novel therapeutic approaches: highlighting targeted, antibody and supportive care therapies

11:30 **Case study: A phase I-directed, non-clinical development strategy for a CDK-/kinase inhibitor: establishing non-clinical data to give guidance on phase I trial design in terms of the determination of safety/efficacy relevant endpoints and early warning signs for adverse effects**

- A non-clinical testing strategy: an overview (PD, PK and toxicology)
  - Specific aspects of individual non-clinical safety studies
  - Dealing with drug-specific, non-clinical study findings
  - Non-clinical study results and their impact on phase I clinical trial designs
  - Regulatory feedback and overcoming related issues
- Thorsten Meyer, Associate Director, GPC BIOTECH**

12:00 **Case study: IPH 2101, a novel anti-Natural Killer Immunoglobulin like Receptor (KIR) monoclonal antibody that enhances NK cells cytotoxicity: preclinical and phase I studies results in various hematological malignancies**

- NK cell activation as a novel immunotherapy approach for the treatment of hematological cancers
  - Pre-clinical development: pharmacodynamic and pharmacokinetic aspects and relevance of preclinical models
  - Modelisation for dose ranging to be tested in phase I
  - Designing the first in man study: selecting safe starting dose and escalation scheme
  - Selection of indications to be tested in phase II and impact of potential surrogate endpoints
- Patrick Squiban, Chief Medical Officer, EVP Medical and Regulatory Affairs, INNATE PHARMA**

12:30 **Case study: Phase II trial designs in oncology: what really matters to ensure an optimum outcome using common and innovative methods and prevent failure of the trial at a later stage**

- Establishing the purpose of phase II trials
  - Assessing the success rate of phase III trials
  - Outlining factors to reduce the number of failures
  - Benefitting from using innovative ways to assess tumour burden
  - Setting up statistical trial designs for phase II
  - Validating biomarkers effectively
- Christiane Langer, Group Director Early Oncology, BRISTOL-MYERS SQUIBB EUROPE**

13:00 *Lunch*

14:00 **Overcoming operational challenges in large phase III oncology studies**

- Choosing and managing CROs by proactively building a strong relationship with them
- Gaining access to laboratory and imaging data in a timely manner
- Considering the use of pharmacogenomics when running global clinical trials in order to evaluate scientific differences accurately
- Describing new testing systems and trial strategies based on the genetic differences of patients
- Monitoring the trial processes and increasing investigator site performance and productivity
- Understanding regulatory issues: how to get the right information and guarantee compliance with data guidelines
- Exploring approaches to speed up clinical operations processes to optimise the trial outcome

**Denis Mir, Senior Manager, Clinical Operations – Oncology, EISAI GLOBAL CLINICAL DEVELOPMENT**

14:30 **Supportive care in oncology: challenges and opportunities in drug development to improve outcomes for patients**

- Emerging areas of toxicity with new therapies
- Meaningful endpoints in supportive care
- Specific challenges in running supportive care studies
- Patient reported outcomes and the regulatory perspective
- Old drugs for new problems

**Julian D. Howell, Head of Clinical Development, PROSTRAKAN**

15:00 **Case study: Outlining skin toxicity of targeted therapies: epidemiology and management**

- Understanding cancer epidemiology and clinical presentation
- Managing skin toxicity from a scientific perspective
- Clarifying international guidelines
- Skin toxicities in clinical trials: presenter's experience
- Establishing a guide for patients
- Investigator education

**Thomas Bogenrieder, Clinical Director Oncology, Oncology Centre of Excellence, Europe, Asia-Pacific, Japan & Emerging Markets, GLAXOSMITHKLINE**

15:30 *Afternoon refreshments*

16:00 **Combining targeted cancer therapies successfully: what are the possibilities, crucial factors to be considered and solutions to benefit from?**

- Deciding whether to combine targeted therapies or run sequential therapies: outlining the benefits of combination
- Explaining how to handle toxicity issues when complying with safety guidelines
- Leveraging synergetic effects of combined targeted therapies: how to make your targeted therapies more effective
- Exploring how to maximise the effectiveness of a targeted therapy choosing the right complementary therapy
- Outlining the combination opportunities between targeted therapy and radiotherapy: decisive parameters for an optimal combination
- Combining targeted therapy and chemotherapy: how to merge schedules effectively
- Creating strategies for reaching a balance between efficacy and safety to optimise the overall outcome of the combined targeted therapy

**Murray Yule, Vice President Clinical Development, ASTEX THERAPEUTICS**

16:30 **Case study: Addressing the challenge of historical efficacy data in the design of a phase III study for a placebo-controlled chemotherapy trial**

- Ensuring effective product development and understanding the resulting clinical efficacy data for adjuvant instillation therapy of gemcitabine in patients with non-muscle-invasive bladder cancer (NMIBC): An analysis following the outcome of a phase III trial: single postoperative instillation of gemcitabine in patients with NMIBC, reviewing the results of a randomised, double-blind, placebo-controlled phase III multicentre study
  - Creating an effective study design based on an in vitro cell line, animal data, phase II data of the experimental drug and understanding of the phase III data for the control arm
  - Presenting an overview of an unplanned interim analysis: follow-up during the study was terminated after only approximately 50% of recurrences occurred at the initially planned follow-up-period
  - Understanding why final results showed not different but unexpected high rates for (recurrence-free survival RFS) in both arms
- Clarifying contributing factors to results: exploring the "experimental" setting of the placebo arm (instillation of saline)**
- Clemens Stoffregen, Internist, Regional Tumour Team Leader, European Platform, Oncology, Medical Advisor, LILLY**

## Understanding new regulatory considerations surrounding cancer clinical trials

### 17:00 Explaining amendments to clinical trials guidelines in terms of continuous safety monitoring and reporting requirements

- Clarifying Eudralex Volume 10:
  - New additions: Q&A document on safety reporting
  - Detailed guidance on the collection, verification and presentation of adverse reaction reports arising from clinical trials on medicinal products for human use
  - Guidance on Investigational Medicinal Products (IMPs) and other medicinal products used in clinical trials
- International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH): exploring the revision of the Development Safety Update Report guideline  
**Janet Schriever, Unit Clinical Trials, BFARM**

### 17:30 Closing remarks from the Chair and champagne prize draw

## Who should attend:

**Directors, senior managers and managers from the following areas within pharmaceutical manufacturers and biotech companies:**

- Oncology clinical trials
- Clinical research & development, clinical trials, clinical operations
- Medical affairs, medical department
- Drug development
- Biochemical engineering
- Biostatistics, statistics
- Pre-clinical research, development
- Pharmacokinetics and dynamics
- Biomarker
- Imaging
- Business unit oncology, therapeutic area oncology
- Marketing
- Regulatory affairs
- External affairs

## TESTIMONIALS – previous attendees' thoughts:

"Overall the experience was positive. It's good to hear the opinions of colleagues"

**Associate Professional, Investigational Supplies, Johnson & Johnson**

"Very good & informative"

**Clinical Liaison, Amgen**

"The conference was very well organised and the subjects were very diverse. . . I would recommend this to others"

**Senior Research Associate, Wyeth**

"Very relevant to our situation."

**Corporate Director, Integrated Supply Chain, Laboratoires Serono**

# Drug targeting in cancer clinical trials: establishing potential developmental pathways

**MONDAY 30 NOVEMBER 2009**

**Steen Knudsen, PhD, CSO and Founder, MEDICAL PROGNOSIS INSTITUTE**

## About the workshop:

Drug targeting is traditionally based on a single DNA or protein marker that separates responders from non-responders. However, gene expression is emerging as a universal approach that works where single markers fail. This workshop will explain how gene expression can be used for drug targeting in cancer.

## About the workshop leader:

Steen Knudsen, PhD, is CSO and founder of Medical Prognosis Institute in 2004. He has worked for more than 10 years with gene expression, bioinformatics, cancer and clinical trials and is the author of numerous papers as well as three books on the subject. He previously held a position as Professor in academia. The Medical Prognosis Institute is a Danish pharmacodiagnostic company with proprietary pivotal technology (DNA microarray, qPCR based) which is universally applicable to any drug and any disease to determine drug response prediction. MPI offers this technology as a service to pharma and biotech companies e.g. with a pipeline of cancer, diabetes or obesity drugs.



## Workshop agenda:

- 09:00 **Exploring a universal approach to drug targeting in oncology: gene expression**
- Explaining the process of developing a predictor
  - What are the requirements?
  - Identifying clinical validation results
- 09:45 **Selecting the most promising cancer types for phase I/II trials**
- Demonstrating which cancer types will give high response rates by assessing a response predictor
  - Highlighting examples from the drug industry
- 10:15 *Morning refreshments*
- 10:45 **Outlining trial designs for targeted drugs: large potential savings in trial size**
- Selecting patients for inclusion
  - Testing the predictor after trial completion
- 11:30 **Explaining economic aspects of drug targeting**
- Reducing patient population through drug targeting but not market size
  - Clarifying why drug targeting is an insurance against failure in phase III
- 12:00 **Presenting a brief overview of regulatory aspects of drug targeting**
- Outlining how regulatory authorities have prepared for approval of more targeted drugs
- 12:15 **End of workshop**

## Do you wish to exhibit your products and services at this exclusive event?

If you want to be part of this leading industry event, please contact Rizwan Qayum in our sponsorship team. Email: [rizwanqayum@arena-international.com](mailto:rizwanqayum@arena-international.com) or call: +44 (0) 020 7753 4259

## Supporting Associations



**ASCO** is the world's leading professional organization representing physicians who treat people with cancer. ASCO's members set the standard for patient care worldwide and lead the way in carrying out clinical research aimed at improving the prevention, diagnosis, and treatment of cancer.



**The European Society for Medical Oncology (ESMO)** is the leading non-profit European professional organization focusing on advancing the specialty of medical oncology and promoting a multidisciplinary approach to cancer treatment

and cure. ESMO is an international community of more than 6,000 oncology professionals, spanning over 100 countries. We unite key stakeholders who share the common objective of eradicating cancer, fostering a favorable environment for scientific research, and advocating for equal access to the best and most effective patient treatment and care available. Our tradition of excellence in state-of-the-art educational and training programs provide the oncology community with platforms to disseminate the most up-to-date scientific research and information available. ESMO's scientific journal, *Annals of Oncology*, ranks among the top clinical oncology journals worldwide. Recognized as an authoritative voice in the fight against cancer, ESMO is pleased to offer consultative expertise to oncology organizations and European authorities on important issues related to cancer research, prevention, diagnosis, treatment and cure. [www.esmo.org](http://www.esmo.org)

## Lead sponsor



**Nexus Oncology** is a specialist CRO offering oncology drug development services to the biopharmaceutical sector. Founded over 10 years ago, we maintain a commitment and focus to the conduct of oncology studies across Europe, the US and beyond. We work

100% in oncology. As such, our clients benefit from staff with a significant degree of specific experience in the highly specialised arena of clinical oncology research. Originally specialising in Phase I oncology studies we have successfully extended our area of expertise into phase II and phase III. In doing so we have expanded our UK base and have offices in France, Switzerland, Poland, Sweden and Hungary supplemented by an extensive network of field based staff throughout Europe. We also have operations in North America, headquartered in San Antonio, with satellites in San Diego and Atlanta, and again, field based staff covering the whole region. Nexus primarily provide clinical and medical monitoring, project management, regulatory services, feasibility and development planning services. Through our network of excellent strategic partners we are able to offer clinical services in extended geographies as well as biometrics, central labs, drug supply and pharmacovigilance enabling Nexus to offer full service whenever a client requires. Nexus has an enviable reputation for high quality people and data, long standing relationships with oncologists the world over and real client focus. [www.nexusoncology.com](http://www.nexusoncology.com)

## Silver sponsors



**RadPharm** partners with pharmaceutical, biotechnology and medical device companies to manage all facets of the imaging segment

of global clinical trials, Phase I-IV. We provide centralized, independent, blinded interpretation of medical imaging for clinical studies and a proven planning, tracking and implementation process, from protocol design through regulatory submission. [www.radpharm.com](http://www.radpharm.com)



Harrison  
Clinical  
Research

**Harrison Clinical Research**, a globally working CRO (ISO 9001) with offices in Europe, Israel and USA and partners in Asia offers full service (including development strategy, project management and performance, monitoring, data management, biostatistics, medical writing, auditing, training, outsourcing) for clinical phase I (in own clinic) to phase IV trials.



**Cmed** provides CRO services and unique clinical data technology. Services include: clinical project management and monitoring, data management (eDC/paper) and statistical services. Cmed is rapidly gaining a reputation for leadership in the adaptive trial design community through its unrivalled ability to conduct complicated adaptive design studies using patented intelligent data acquisition/management (IDAM) technology. As Cmed combines both CRO services and technology within a single organisation it can execute these studies particularly efficiently without sponsors to coordinate

multiple service providers. [www.cmedresearch.com](http://www.cmedresearch.com)



**PPD** is a leading global contract research organisation providing discovery, development and post-approval services as well as compound partnering programmes. Our clients and partners include pharmaceutical, biotechnology, medical device, academic and government organisations. With offices in 38 countries and more than 10,000 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a commitment to quality to help its clients and partners maximise returns on their R&D investments and accelerate the delivery of safe and effective therapeutics to patients. For more information, visit our Web site at [www.ppd.com](http://www.ppd.com).

## Sponsor



## Co-sponsor



## Exhibitors



## Media partners



**ClinPage** is a daily online news resource dedicated to clinical trial technologies and services. It is the only publication in any medium focused on the complex trends, tools and processes that support clinical trials. ClinPage engages the reader with an interactive conversation featuring industry leaders and up-to-the-minute news. Covering how clinical data is managed [www.ClinPage.com](http://www.ClinPage.com)

**b3c NEWSWIRE** **b3c newswire** is the leading PR distribution service for biotech press releases. With more than 1,500 media titles worldwide we have the largest reach in biotech/pharma trades. Due to our "specialized channels" an excellent visibility of your news is assured. [www.b3cnewswire.com](http://www.b3cnewswire.com)



**Pharmaceutical Business Review** The Business Review websites are your number one stop for all the latest news, comment and industry information. For further information contact [jsharp@industryreview.com](mailto:jsharp@industryreview.com)

**ecancermedalscience** **ecancermedalscience**, the peer reviewed, online open access journal from the European Institute of Oncology, is targeted at oncology professionals, publishing new, innovative research along with multimedia extras – video, news and blogs. **ecancer** aims to improve communications between sub-specialised cancer scientists and clinicians by working interactively and quickly.



**Breast Cancer Research** is an international, peer-reviewed online journal edited by Professor Lewis Chodosh. Research articles are published in all areas of biology and medicine relevant to breast cancer, with special emphasis on the genetic, biochemical, and cellular basis of breast cancer. Contact us at [www.breast-cancer-research.com](http://www.breast-cancer-research.com)



Every weekly issue of **Cancer Drug News** reports the important news on the companies, products, alliances and research that are shaping global cancer markets with regular sections on cancers affecting the brain, breast, GI tract, genito-urinary system, gynaecological system, blood and lung as well as melanoma/sarcoma. For further information please visit: [www.espicom.com/cdn](http://www.espicom.com/cdn)

**pharmaceutical-  
technology.com**  
The website for the pharmaceutical industry

**drugdevelopment-  
technology.com**  
For every phase of your drug development

## Supporting association



# BOOKING FORM

2nd Annual Clinical Trials in Oncology, Tuesday 1 and Wednesday 2 December 2009, Hilton Munich City, Munich, Germany

## Prices & Payment Information (please tick option)

Yes, i would like to register for the event:	BEFORE 8.9.2009	BEFORE 6.10.2009	BEFORE 3.11.2009	AFTER 3.11.2009
<b>Pharma and Biotech manufacturers</b>				
<input type="checkbox"/> I would like the VIP Attendee Package to include the 2 day conference + workshop + the interactive CD-ROM (saving €70)	€2,989 (VAT where applicable)	€3,129 (VAT where applicable)	€3,269 (VAT where applicable)	€3,479 (VAT where applicable)
<input type="checkbox"/> I would like to attend the two day conference only	€1,820	€1,960	€2,099	€2,390
<input type="checkbox"/> I would like to attend the two day conference + workshop	€2,359	€2,499	€2,639	€2,849
<input type="checkbox"/> I would like to attend the workshop only	€599	€739	€879	€1,089
<b>Academic/Government representatives</b>				
<input type="checkbox"/> I would like the VIP Attendee Package to include the 2 day conference + workshop + the interactive CD-ROM (saving €70)	€2,079 (VAT where applicable)	€2,219 (VAT where applicable)	€2,259 (VAT where applicable)	€2,569 (VAT where applicable)
<input type="checkbox"/> I would like to attend the two day conference + workshop	€1,499	€1,589	€1,729	€1,939
<input type="checkbox"/> I would like to attend the two day conference only	€910	€1,050	€1,190	€1,400
<b>Fees for all other attendees</b>				
<input type="checkbox"/> I would like the VIP Package attendees package to include the two day conference + interactive CD-ROM	€3,450 (VAT where applicable)	€3,590 (VAT where applicable)	€3,730 (VAT where applicable)	€3,940 (VAT where applicable)
<input type="checkbox"/> I would like to attend the two day conference	€2,820	€2,960	€3,100	€3,310
<input type="checkbox"/> I cannot attend the conference but would like to receive the interactive CD-ROM	€700 + VAT	€700 + VAT	€700 + VAT	€900 + VAT

Total  Discount code if applicable   
Discounts are at the discretion of VIBEvents and are not cumulative

## Four Easy Ways To Book:

- Register online at [www.clinicaltrialevents.com/oncology](http://www.clinicaltrialevents.com/oncology)
- Email us at [events@arena-international.com](mailto:events@arena-international.com)
- Tel +44 (0)20 7753 4268
- Fax +44 (0)20 7915 9773

### Venue Details

The two day conference will take place on Tuesday 1 and Wednesday 2 December 2009. The venue for all two days will be in Munich, Germany. For further information contact our Operations department on +44 (0) 207 753 4201.

### Are you registered?

You will always receive an acknowledgement of your booking. If you do not receive anything, please call us on +44 (0) 20 7753 4268 to make sure we have received your booking.

### Arena International Conference Delegate terms and conditions

1 Scope of Agreement: These are the conditions of the contract between you, the Client ("You" and "your") and Arena International Events Group ("Arena International Events Group", "we", "us" and "our") governing your use of our services, including the conference registration as set out in your booking form. This agreement constitutes the entire agreement between Arena International Events Group and you. All prior agreements understandings and negotiations and representations (save for fraudulent misrepresentation) whether oral or in writing are cancelled in their entirety. The terms of any other electronic communications will not form part of this agreement.

2 Our commitment to you: Should the Event be cancelled or the location be changed for reasons or circumstances beyond our control, we reserve the right to reschedule the Event, including changing the location, upon written notice to you. Should the event fail to be rescheduled for any reason your refund shall not exceed the total charge received by us from you.

3 Payment Terms: The Total Fees specified on the booking form are subject to an additional service charge of 2.5% ("Service Charge") applied to cover administration costs, and are exclusive of VAT and any other applicable sales tax which shall be payable in addition.

• Following completion and return of the booking form, full payment including Service Charge is required within five days from the invoice date or prior to the event if this is sooner. All registrants must provide a credit card number as a guarantee at the time of booking. We reserve the right to charge your card in full if payment is not received in accordance with these payment terms. We reserve the right to refuse admission if full payment is not received in accordance with these terms.

4 Cancellations: In the event of cancellation, 100% of the event fee is payable and non-refundable. All cancellation requests must be submitted to us in writing. If we agree to your cancellation then all cancellation fees are payable immediately after the acceptance of your cancellation in writing by us.

5 General: You, your executive/s or your agents may not transfer or assign any of the rights or obligations of this Agreement (in whole or part) without our prior consent. Any attempt to resell, assign or transfer rights without our consent will entitle us to cancel the contract without liability to you.

• This agreement is governed by and will be construed in accordance with English law and each party irrevocably agrees that the courts of England will have the non-exclusive jurisdiction to deal with any disputes arising out of or in connection with this agreement.

• Grant of Licence: If your booking includes the CD-ROM, you warrant that you will only use the CD-ROM for your business purposes and shall not, without our prior written consent, make available, copy, reproduce, transmit, disseminate, sell, licence, distribute, publish, broadcast or otherwise circulate the CD-ROM (or any part of it) to any other person other than in accordance with these terms and conditions.

• Arena International Events Group is subject to the UK Data Protection Act 1998 and is registered in the UK with the Information Commissioner to process your personal information. Our primary goal in collecting personal information from you is to give you an enjoyable customised experience whilst allowing us to provide services and features that most likely meet your needs. We collect certain personal information from you, which you give to us when using our Sites and/or registering or subscribing for our products and services. We also collect certain personal data from other group companies to whom you have given information through their websites. If you do not want us to continue using this information please notify us at [unsubscribe@arena-international.com](mailto:unsubscribe@arena-international.com). Any personal information supplied to SPG Media Ltd as part of this registration process and/or any other interaction with SPG Media Ltd will be collected, stored and used by SPG Media Ltd its subsidiaries, related companies or affiliates in accordance with the SPG Media Ltd Privacy Policy. Please email [privacypolicy@arena-international.com](mailto:privacypolicy@arena-international.com) for a copy of the SPG Media Ltd Privacy Policy.

• The working language of the Event is English. Executives requiring an interpretation service must make their own arrangements at their own expense.

Arena International Events Group, a trading division of SPG Media Ltd. Registered Office: 55 North Wharf Road, London, W2 1LA, UK. Registered in England No. 01155599. [www.arena-international.com](http://www.arena-international.com)

### Delegate Details please photocopy form for multiple bookings

Mr/Mrs/Ms/Dr:  First Name:  Surname:   
Email:  Tel:  Job Title:   
Fax:  Department:   
**Company Details**  
Company:  Address:   
Town:  Postcode:  Country:   
VAT Number:  Nature of Business:

### Payment Details

Purchase Order No.

- I enclose a cheque drawn on a UK bank (please make cheque payable to VIBEvents and write reference CTO1209 on the reverse)
- I will transfer payment to your Lloyds TSB account City Branch, London, UK: 01492549, sort code 30-00-02 (using reference CTO1209)
- I would like to pay with my credit card  Visa  Mastercard  AMEX  Maestro  Solo

Card Number:  Expiry Date:  Issue Date:  CSV\*:

Cardholder's Name:

Cardholder's Address:

\*The CSV number is the last 3 digit number on the reverse of the card

- Yes, I have read and understood the terms and cancellations conditions and am happy to proceed with my registration

Signature  Date